Endovascular thrombectomy for acute ischemic stroke with a large infarct area: an updated systematic review and meta-analysis of randomized controlled trials

1. Shivani Ravipati shivani98.ravipati@gmail.com
   Department of Medicine, Dr.Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation, India.

2. Ayesha Amjad aishaamjad03@gmail.com
   Department of Medicine, Sargodha Medical College, Pakistan.

3. Komal Zulfiqar kzali98@yahoo.com
   Department of Medicine, Allama Iqbal Medical College, Pakistan.

4. Hannah Biju hannahbiju1974@gmail.com
   Department of Medicine, Kristu Jayanti College, India.

5. Wajeeh Hassan wajeehere@gmail.com
   Department of Medicine, Allama Iqbal Medical College, Pakistan.

6. Haider Mumtaz Jafri haidermumtaz63@gmail.com
   Department of Medicine, Rahbar Medical and Dental College, Pakistan.

7. Ali Husnain ali.husnain@northwestern.edu
   Department of Radiology, Northwestern University, U.S.A.

8. Ibrahim Tahir ibrahimtahir274@gmail.com
   Department of Medicine, Sheikh Khalifa Bin Zayed Al Nahyan Medical and College, Pakistan.

9. Muaaz Aslam Muaazaslamy92ict@gmail.com
   Department of Medicine, Sheikh Khalifa Bin Zayed Al Nahyan Medical and College, Pakistan.

10. Sharib Afzal Sharibbughio@gmail.com
    Department of Medicine, Ziauddin University, Pakistan.

11. Muhammad Ehsan* m.ehsanqadri@gmail.com
Department of Medicine, King Edward Medical University, Pakistan

12. Huzaifa Ahmad Cheema huzaifaahmadcheema@gmail.com

Department of Medicine, King Edward Medical University, Pakistan

13. Muhammad Ayyan iamayyan77@gmail.com

Department of Medicine, King Edward Medical University, Pakistan

14. Wajeeh Ur Rehman wajeeh.rehman9@gmail.com

Department of Medicine, United Health Services, Johnson City, New York

15. Sourbha S. Dani sourbha.dani@gmail.com

Department of Cardiology, Lahey Hospital and Medical Center, Burlington, MA

*Corresponding Author:

Muhammad Ehsan, M.B.B.S.

Affiliation: Department of Medicine, King Edward Medical University, Pakistan

Email address: m.ehsanqadri@gmail.com

Phone Number: +923046720007

Keywords: meta-analysis; endovascular thrombectomy; large ischemic stroke; mechanical thrombectomy

Statements and Declarations

Ethical Publication Statement

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Declarations of interest

The authors declare that they have no conflicts of interest and no financial interests related to the material of this manuscript.

Funding

No financial support was received for this study.

Acknowledgments

N/A
Data Availability Statement

Data will be provided on reasonable request from the corresponding author.

Abstract

Background

Since the efficacy and safety of endovascular thrombectomy (EVT) in patients with acute ischemic stroke with a large infarct area is still inconclusive, we sought to compare functional and neurological outcomes with the use of endovascular thrombectomy versus medical care alone.

Methods

We searched MEDLINE (via PubMed), Embase, Cochrane Library, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) to retrieve all the relevant randomized controlled trials (RCTs) on this topic. Review manager (RevMan) was used to perform meta-analyses using a random-effect model. Dichotomous outcomes were pooled using risk ratios (RR) with 95% confidence intervals (CIs).

Results

Our meta-analysis included 6 RCTs with a total of 1665 patients. Most studies included patients with an ASPECTS score of 3-5. Our results demonstrate that endovascular thrombectomy significantly increased the rates of functional independence (mRS ≤ 2) (RR, 2.49; 95% CI, 1.89-3.29) and moderate neurological outcome (mRS ≤ 3) (RR, 1.90; 95% CI, 1.50-2.40) at 90 days. The benefit of EVT for these outcomes remained the same at 1-year follow-up. Endovascular thrombectomy was associated with increased rates of early neurological improvement (RR, 2.22; 95% CI, 1.53-3.22), excellent neurological recovery (mRS ≤ 1) (RR, 1.75; 95% CI, 1.02-3.03), and decreased rate of poor neurological recovery
(mRS 4-6) (RR, 0.81; 95% CI, 0.76-0.86). No significant difference was found between the two groups regarding all-cause mortality (RR, 0.86; 95% CI, 0.72-1.02), decompressive craniectomy (RR, 1.32; 95% CI, 0.89-1.94), and the incidence of serious adverse effects (RR, 1.39; 95% CI, 0.83-2.32) between the two groups. Endovascular thrombectomy significantly increased the rates of any intracranial hemorrhage (RR, 1.94; 95% CI, 1.48-2.53) and symptomatic intracranial hemorrhage (RR, 1.73; 95% CI, 1.11-2.69).

Conclusion

Endovascular thrombectomy (EVT) significantly improves neurological and functional outcomes in patients with acute ischemic stroke with a large infarct area (ASPECTS 3-5) compared to medical therapy alone, with an increased risk of symptomatic intracranial hemorrhage.

Keywords: meta-analysis; endovascular thrombectomy; large ischemic stroke; mechanical thrombectomy

Introduction

Over the last decade, studies have showcased a clear benefit of endovascular thrombectomy (EVT) over medical therapy (MEDT) alone in managing acute ischemic stroke (AIS) due to large vessel occlusion (LVO) (1). Therefore, current guidelines advocate for EVT in individuals presenting with Alberta Stroke Program Early CT Score (ASPECTS) ≥6 (range: 0-10, inverse relation with the infarction size) (2,3). However, patients with large-core infarct (LCI) – defined as ischemic volume greater than 50 mL or 70 mL with cerebral perfusion <30%, or ASPECTS <6 – were not considered candidates for EVT due to the potential risk of reperfusion injury, hemorrhagic conversion, and perception of negligible advantage as a notable portion of brain tissue being already infarcted in these patients (4).
The management of this patient population, constituting one-fourth of LVO cases, revolved mainly around curtailing secondary insult from raised intracranial pressure and cerebral edema in the background of large ischemic volume. Frequently applied approaches included but not limited to optimizing cerebral blood flow and diligent blood pressure monitoring, bolstering collateral circulation in at-risk tissue, seizure identification, and management, and preventing recurrent recurrence (4,5). In brief, the LCI stroke population remained underrepresented for a long time in studies assessing the benefits of EVT over MEDT.

RESCUE-Japan LIMIT trial by Yoshimura et al. was the first randomized controlled trial (RCT) to evaluate the efficacy and safety of EVT in this subset population (6). The trial reported favorable outcomes in the EVT arm compared to MEDT alone and paved the way for further studies. As a result, five more RCTs have been conducted to date (5,7–10). Several meta-analyses meticulously combine the results of published trials in the literature (1,11–13). However, these reviews, do not include all trials as results from some trials, such as LASTE, were reported after publication. They do not include all trials as results from some trials, such as LASTE, were reported after publication (10). Furthermore, we also incorporated the 90-day results from the TESLA and SELECT2 trials, which helped assess the long-term efficacy of EVT (14,15).

This updated meta-analysis aims to comprehensively synthesize the latest results from all trials, offering higher-level insight into the efficacy and safety of EVT and MEDT vs. MEDT alone.

**Materials and methods**

This systematic review and meta-analysis followed the guidelines outlined in the Cochrane Handbook for Systematic Reviews (16) and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (17). Ethical approval
was not required for this study. The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the identifier CRD42023492739.

**Data Sources and Search Strategy**

Electronic searches were conducted using various online databases from inception to December 2023. These included the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (via PubMed), Embase (via Ovid), ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP). No geographical or language restrictions were applied during the search process. Additionally, the reference lists of the included studies and similar systematic reviews were screened to retrieve relevant articles. The detailed search strategy for MEDLINE is given in Supplementary Table 1.

**Eligibility Criteria**

The inclusion criteria for the study were as follows: (1) study design: randomized controlled trials (RCT); (2) population: individuals with large ischemic stroke, defined as a large vessel occlusion with an ASPECTS score of 3 to 5; (3) intervention: endovascular thrombectomy plus medical therapy; (4) control group: medical therapy alone; and (5) outcome: reporting at least 1 outcome of interest.

The exclusion criteria were as follows: (1) study designs other than RCTs, such as quasi-randomized trials, reviews, and observational studies; (2) studies conducted on animals; and (3) studies evaluating outcomes in patients who have undergone ischemic stroke with a small infarct area.

**Study Selection**
The literature search results were imported into Zotero, a software management tool for screening articles. After de-duplication, two authors independently conducted the initial phase of screening titles and abstracts. The full-text screening was performed on the remaining studies, and a final selection was made based on adherence to our eligibility criteria. A third author settled any disagreements regarding the selection of the studies. The selection process is presented in the form of a PRISMA flow chart.

**Data collection process and data items**

Two review authors extracted data from the included studies into a pre-piloted structured Excel spreadsheet. Relevant data items were extracted, including study characteristics (country, study design, total participants, intervention, main inclusion criteria, ASPECTS score, study follow-up duration, and baseline imaging), baseline characteristics (age, sex, number of patients in each group, NIHSS score, infarct core volume, ASPECTS score, and occlusion location), primary outcomes (functional Independence (mRS ≤ 2) and moderate neurological outcome (mRS ≤ 3)), and secondary outcomes (all-cause mortality at 90 days, early neurological improvement, excellent neurological recovery (mRS ≤ 1), poor neurological recovery (mRS ≤ 4-6), any intracranial hemorrhage, symptomatic intracranial hemorrhage, decompressive craniectomy, and >1 SAE (serious adverse effect).

**Risk of Bias and Quality Assessment**

The risk of bias was assessed in the included studies using the revised Cochrane Risk of Bias Tool for randomized controlled trials (RoB 2.0) (18). The domains that were evaluated included (1) risk of bias resulting from the randomization process, (2) risk of bias due to deviation from the intended intervention, (3) risk of bias due to missing outcome data, (4) risk of bias in measuring the outcome, (5) risk of bias in selecting the reported results, and (6)
other bias. For clarification, "low" indicates a low risk of bias, and "high" indicates a high risk of bias. If the study lacked information or had uncertainty over the potential for bias, the item was judged as "unclear." Any disagreements in evaluating the risk of bias were resolved through discussion to reach a consensus between the two authors. A third author served as an arbiter if needed.

**Statistical Analysis**

Statistical analyses were performed using the Review Manager software (version 5.3; RevMan v5.3). The DerSimonian-Laird variance estimator was used to apply a random effects model. Dichotomous outcomes were pooled using risk ratios (RR) with 95% confidence intervals (CIs). Heterogeneity was assessed using the chi-square and I-square tests. The alpha level for the chi-square test was set at 0.1, as determined by the Cochrane Handbook, and was considered to suggest statistically significant heterogeneity.

**Results**

**Search Results and Study Selection**

A total of 2077 studies were identified from various databases. Following deduplication and initial screening, 55 full-length articles were assessed for eligibility. A total of 6 RCTs were included in our systematic review and meta-analysis. The detailed screening process is illustrated in the PRISMA flowchart (Figure 1)

**Characteristics of Included Studies**

We included 6 RCTs in our meta-analysis (5–10). A total of 1665 patients were included, of which 945 received endovascular thrombectomy with medical therapy, and 942 received medical therapy alone. All studies except LASTE included patients having a pre-stroke mRS score of 0–1 and a stroke with a large ischemic-core volume, defined as an ASPECT score of
3 to 5. The follow-up duration was 90 days in all the studies. Reports of two studies reporting outcomes at 1-year follow-up have also been included in this systematic review. Detailed characteristics of included studies are given in Table 1.

**Risk of Bias and Quality of Evidence**

We used Cochrane RoB2 to evaluate the risk of bias of included studies. All six RCTs were deemed to have a low risk of bias [Figure 2].

**Primary Outcomes**

**Functional Independence (mRS \(\leq 2\))**

Our meta-analysis of 6 trials indicates that endovascular thrombectomy significantly increased the rate of functional Independence (mRS \(\leq 2\)) at 90 days (RR, 2.49; 95% CI, 1.89-3.29; Figure 3). The heterogeneity reported between studies for this outcome was low (\(I^2 = 7\%\)). A meta-analysis of only two trials found endovascular thrombectomy to significantly increase the rate of functional Independence (mRS \(\leq 2\)) at 1 year (RR, 3.84; 95% CI, 2.35 – 6.29; Supplementary Figure 1) with minimal heterogeneity (\(I^2 = 0\%\)).

**Moderate Neurological Outcome (mRS < 3)**

Endovascular thrombectomy significantly increased the rate of independent ambulation (also known as moderate neurological outcome) compared to medical therapy (RR, 1.90; 95% CI, 1.50-2.40; Figure 4). Statistical heterogeneity was found to be moderate (\(I^2 = 51\%\)).

A meta-analysis of only two trials found endovascular thrombectomy to significantly increase the rate of independent ambulation (mRS \(\leq 3\)) at 1 year (RR, 2.08; 95% CI, 1.56 – 2.77; Supplementary Figure 2) with minimal heterogeneity (\(I^2 = 0\%\)).

**Secondary Outcomes**

**Early Neurological Improvement**
Our meta-analysis found that endovascular thrombectomy increased the rate of early neurological improvement (RR, 2.22; 95% CI, 1.53-3.22; Supplementary Figure 3) with minimal statistical heterogeneity ($I^2 = 17\%$).

**Excellent Neurological recovery (mRS ≤ 1)**

Endovascular thrombectomy was associated with an improved rate of excellent neurological recovery (mRS ≤ 1) as compared to medical therapy alone (RR, 1.75; 95% CI, 1.02-3.03; Supplementary Figure 4). The inter-study statistical heterogeneity was estimated to be low ($I^2 = 36\%$).

**Poor Neurological Recovery (mRS 4-6)**

Endovascular thrombectomy was associated with a significantly decreased rate of poor neurological recovery (mRS 4-6) as compared to medical therapy alone (RR, 0.81; 95% CI, 0.76-0.86; Supplementary Figure 5) with minimal statistical heterogeneity ($I^2 = 0\%$).

**All-cause Mortality**

No statistically significant difference was found between the two groups regarding all-cause mortality (RR, 0.86; 95% CI, 0.72-1.02; Supplementary Figure 6) with moderate statistical heterogeneity ($I^2 = 45\%$).

**Symptomatic Intracranial Hemorrhage**

Endovascular thrombectomy significantly increased the rate of symptomatic intracranial hemorrhage (RR, 1.73; 95% CI, 1.11-2.69; Supplementary Figure 7). Statistical heterogeneity was found to be minimal ($I^2 = 0\%$).

**Decompressive craniectomy**
No statistically significant difference was found between the two groups regarding decompressive craniectomy (RR, 1.32; 95% CI, 0.89-1.94; Supplementary Figure 8). Statistical heterogeneity between studies was low ($I^2 = 41\%$).

**Any intracranial hemorrhage**

Endovascular thrombectomy significantly increased the rate of any intracranial hemorrhage (RR, 1.94; 95% CI, 1.48-2.53; Supplementary Figure 9). The estimated heterogeneity was substantial ($I^2 = 72\%$).

**>1 SAE**

Our meta-analysis showed no significant difference in rates of serious adverse effects between the two groups (RR, 1.39; 95% CI, 0.83-2.32; Supplementary Figure 10) with substantial heterogeneity ($I^2 = 93\%$).

**Discussion**

Our meta-analysis included six randomized controlled trials (RCTs), which showed that endovascular thrombectomy (EVT) in combination with medical therapy significantly improves outcomes for patients suffering from large vessel occlusion strokes. EVT increases the likelihood of primary outcomes, i.e., functional independence and moderate neurological outcomes at 90 days, with maintenance of these benefits at 1-year follow-up. Moreover, our analysis indicates that EVT leads to higher rates of early neurological improvement and excellent neurological recovery while reducing the incidence of poor neurological recovery. Despite these benefits, the procedure is associated with an increased risk of symptomatic intracranial hemorrhage; however, it does not significantly affect all-cause mortality or the need for a decompressive craniotomy.
AHA/ASA recommends EVT for patients with an ASPECT score greater than 5. In contrast, those with ASPECT scores below 5 have a poor prognosis and are at risk of symptomatic intracranial hemorrhage (19). Our findings align with the HERMES meta-analysis, suggesting that a lower ASPECT score could still warrant consideration, especially in younger patients (20). There was considerable heterogeneity regarding inclusion criteria among the six trials. The trials in our study had diverse ASPECT scores and ischemic core volumes as their criteria for inclusion, with the majority having ASPECT 3-5. The LASTE trial (10) also included patients with ASPECT scores ranging from 0 to 2. The trials SELECT-2 (5) and ANGEL-ASPECT (7) have incorporated ischemic regions quantified in volumes determined using imaging with more than 50 ml and 70–100 ml, respectively. Our analysis indicated that EVT enhances functional outcomes in post-stroke patients across a wide range of stroke severities, mRS scores, and ischemic volumes.

Our results are consistent with the previous two meta-analyses (21,22), except for the incidence of symptomatic intracranial hemorrhage (sICH); our analysis revealed an increased risk of sICH. This difference can be attributed to including two latest trials, TESLA(8) and LASTE (10). The LASTE trial carried significant weight in the meta-analysis and indicated a heightened risk of sICH, likely accounting for this deviation from earlier reviews.

Considerable heterogeneity was observed in the time elapsed from stroke onset to intervention across all trials. Most trials have set 24 hours as the maximum time for intervention from the time of symptom onset. Notably, the TENSION trial included patients within 12 hours of stroke onset, while the RESCUE Japan LIMIT and LASTE trials included patients who presented within 6 hours of stroke onset. The onset-to-intervention time window is crucial for the patients because the odds of independent ambulation and discharge to home
are reduced by 8% and 10% for every 60 minutes of onset-to-intervention time extended in the early window (within 6 hours). In the late window (6–24 hours), the chances of independent ambulation and discharge to home are 1% and 2% lower for every 60-minute delay in treatment. Hence, early treatment is more favorable for patient recovery and is associated with lower 90-day mortality (23).

ASPECT scores determine the areas with ischemia but do not precisely measure infarction volume or extent. While diagnostic imaging like CT and MRI perfusion can determine the volume of infarcted tissue, it cannot ultimately determine the actual tissue viability. Nevertheless, EVT reperfusion of the ischemic area can be beneficial. The increased blood supply could alleviate edema and remove toxins, leading to neurological recovery regardless of the ischemia area/volume (24,25). Further studies or imaging techniques are required to understand the pathophysiological changes following reperfusion.

The primary strength of our meta-analysis lies in the comprehensive selection of the latest randomized controlled trials (RCTs) and the meticulous adherence to appropriate inclusion and exclusion criteria. Furthermore, we also incorporated the 90-day results from the TESLA and SELECT2 trials (14,15) for our primary outcomes, aiding in the evaluation of the long-term effects of EVT. The inclusion of the latest RCTs with large sample sizes increased the statistical power of our meta-analysis.

However, there are a few limitations to the articles that we included. Firstly, all the studies were of an open-label design, which may introduce bias due to lack of blinding, potentially influencing the outcomes through placebo effects or altered reporting symptoms. Secondly,
early termination of studies or trials might have overestimated the results as premature
consclusions drawn from incomplete data may inflate the perceived benefits of the treatment.
Third, regional specificities observed in studies conducted exclusively in Japan and China,
such as different standard doses of rt-PA and varying prevalences of intracranial artery
stenosis, respectively, could limit our findings' generalizability to a global population.
Additionally, exclusion criteria for patients older than or equal to 80 years used by Huo et al.
(7) might affect generalizability since it excluded a significant portion of the stroke
population from the results.

In addition, two studies focusing on a specific imaging technique (non-contrast CT) raised
concerns about the generalizability of their results to settings where other imaging methods
are commonly used (8,14). Furthermore, patient enrollment criteria based on the ASPECTS
score led to the exclusion of patients with a score higher than 5 and with an infarct core
volume of 70–100 ml in ANGEL-ASPECT And SELECT2 trials, resulting in potential bias
in patient selection that may affect treatment outcomes. Additionally, Yoshimura et al. failed
to document the causes of deaths during the study, raising questions about safety and
associated risks related to the intervention (6).

Limitations in the review process include a small sample size, which might have reduced
statistical power, reducing the ability to detect real differences between groups or variables
being studied, resulting in false negative results and an increased risk of random error
influencing the analysis. Additionally, there is moderate heterogeneity across certain aspects
of our analysis, stemming from variations in study designs, patient populations, treatment
protocols, or outcome measures among the included trials. This variation complicates the
interpretation of specific sub-populations. Furthermore, sub-group analyses could not be
performed based on patient age, stroke severity, or the presence of comorbid conditions, without which our conclusion may overlook significant variations in treatment efficacy. Lastly, individual patient data analysis was not performed due to insufficient data.

Future research should aim to standardize inclusion criteria, particularly regarding ASPECT scores and ischemic core volumes, to enhance and improve comparability among trials and robustness of meta-analysis. Investigating the impact of different inclusion criteria on treatment outcomes could provide valuable insights into patient selection. Long-term follow-up data from trials such as TESLA and SELECT-2 contribute to understanding EVT's sustained benefits. Further studies with extended follow-up periods could elucidate EVT's durability and identify potential late complications or recurrence risks. Future trials should prioritize blinding to minimize possible bias introduced by open-label designs. Additionally, efforts to prevent premature study termination and ensure complete data collection are essential to avoid overestimating treatment effects. Studies should strive for diverse patient populations and global representation to enhance the generalizability of findings. Addressing regional specificities, such as variations in treatment protocols and patient demographics, can facilitate more comprehensive recommendations applicable to diverse healthcare settings.

Overall, while the current evidence supports the efficacy of EVT in ischemic stroke with large infarct areas, ongoing research is essential to optimize patient selection, treatment protocols, and long-term management strategies, ensuring equitable access to effective interventions globally.
Conclusion

Our meta-analysis demonstrates that endovascular thrombectomy (EVT) significantly improves neurological and functional outcomes in patients with acute ischemic stroke with a large infarct area (ASPECTS 3-5) compared to medical therapy alone. However, our findings also indicate a higher risk of symptomatic intracranial hemorrhage associated with EVT. Further studies are needed to evaluate the efficacy of EVT in patients with low ASPECTS scores (1-3) and confirm the safety profile of EVT.

References


15. Thrombectomy Advantage for Large-Core Strokes Widens Over 12 Months: TESLA | tctmd.com [Internet]. [cited 2024 Mar 4]. Available from:


18. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials | The BMJ [Internet]. [cited 2023 Sep 16]. Available from: https://www.bmj.com/content/343/bmj.d5928


Figure Legends

Figure 1. PRISMA 2020 flow chart of included and excluded trials. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Figure 2. Quality assessment of randomized controlled trials (RCTs).

Figure 3. Forest plot of functional independence (mRS ≤ 2) at 90 days follow-up.

Figure 4. Forest plot of independent ambulation (mRS ≤ 3) at 90 days follow-up.
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Country of origin</th>
<th>Trial design</th>
<th>Study follow-up duration</th>
<th>Number of participants</th>
<th>Age (years)</th>
<th>Male (%)</th>
<th>Embolic Intervention</th>
<th>Medical Intervention</th>
<th>ASPECTS, median (IQR)</th>
<th>NIHSS, median (IQR)</th>
<th>Infection core volume, median (IQR)</th>
<th>Occlusion location, N (%)</th>
<th>Median prestroke modified Rankin Scale (IQR)</th>
<th>Intervenous thrombolysis administered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yoshimura et al., 2022</td>
<td>Japan</td>
<td>Multicenter, open-label, randomized clinical trial</td>
<td>90 days</td>
<td>203 (101 vs 102)</td>
<td>76.6±1 0.0 vs 75.7±1 0.2</td>
<td>55 (54.5) vs 58 (56.8)</td>
<td>Stent retriever, aspiration catheter, balloon angioplasty, intracranial stent, and carotid-artery stent</td>
<td>After 30 min</td>
<td>3(3-4) vs 4(3-4)</td>
<td>22 (18-26) vs 22 (27-26)</td>
<td>96 (66-152) vs 110 (76-146)</td>
<td>KA:47 (66.5) vs 49 (68.0)</td>
<td>M1 segment: 76 (73.3) vs 70 (68.6)</td>
<td>M2 segment: 0 vs 3 (2.9)</td>
</tr>
<tr>
<td>Bendixen et al., 2023</td>
<td>Multinational (Europe and Canada)</td>
<td>Multicenter, blinded endpoint, open-labeled</td>
<td>90 days</td>
<td>253 (125 vs 128)</td>
<td>73 (64-81) vs 74 (64-80)</td>
<td>59 (55.0) vs 51 (48.9)</td>
<td>Stent retriever (72/212)</td>
<td>Standard of care (including IV thrombolysis)</td>
<td>3: 36/125 vs 48/128</td>
<td>4: 45/125 vs 39/128</td>
<td>19 (18-22) vs 18 (15-22)</td>
<td>0 (0-1) vs 0 (0-1)</td>
<td>KA: 41,125 (33%) vs 37/127 (29%)</td>
<td>MCA, M1 segment: 83/125 (66.7) vs 80/127 (69%)</td>
</tr>
<tr>
<td>Huo et al, 2023</td>
<td>China</td>
<td>MC open-label</td>
<td>90 days</td>
<td>455 (230 vs 225)</td>
<td>68 (61-73) vs 67 (63-73)</td>
<td>135 (58.7) vs 144 (64.0)</td>
<td>Stent retriever or contact aspiration</td>
<td>After 0.5 mg/kg body weight</td>
<td>3(3-4) vs 3(3-4)</td>
<td>16 (13-20) vs 19 (15-22)</td>
<td>60.5 (29-86) vs 63 (41-86)</td>
<td>KA83 (63.1) vs 581 (66)</td>
<td>M1 Segment: 145 (63) vs 142 (63.1)</td>
<td>M2 Segment: 2 (0.9) vs 2 (0.9)</td>
</tr>
<tr>
<td>Study</td>
<td>Location</td>
<td>Design</td>
<td>Endpoint</td>
<td>Type of Procedure</td>
<td>Lesion Location</td>
<td>Stat. Analysis</td>
<td>p-Value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------</td>
<td>-----------------------------</td>
<td>----------</td>
<td>-------------------</td>
<td>-----------------</td>
<td>---------------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarraj et al., 2022</td>
<td>International (United States, Canada, Europe, Australia, and New Zealand)</td>
<td>Multicenter, Open-label, Blinded</td>
<td>1 year</td>
<td>35(27 vs 17)</td>
<td>66(68-75) vs 67(65-75)</td>
<td>108(40-100) vs 106(34-102)</td>
<td>178(35-78 vs 178(35-78)</td>
<td>1905(19 vs 1905(19)</td>
<td>81.5(57-118) vs 81.5(57-118)</td>
<td>-</td>
<td>331(4.8 vs 331(4.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TREDA 2023</td>
<td>United States</td>
<td>Multicenter, Open-label, Blinded and endpoint, Phase III trial</td>
<td>1 year</td>
<td>300(152 vs 148)</td>
<td>66(64-74) vs 67.5(57.5-73.5)</td>
<td>76(65-75) vs 76(65-75)</td>
<td>120(45-180) vs 120(45-180)</td>
<td>1905(19 vs 1905(19)</td>
<td>160(103-261.5) vs 160(103-261.5)</td>
<td>-</td>
<td>331(4.8 vs 331(4.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LASTE 2024</td>
<td>Europe, United States</td>
<td>Multicenter, Open-label, Blinded and endpoint</td>
<td>90 days</td>
<td>324(150 vs 170)</td>
<td>78(66-79) vs 74(65-80)</td>
<td>80(51.5-65) vs 80(51.5-65)</td>
<td>21(10-26) vs 21(10-26)</td>
<td>-</td>
<td>KA: 69(63.3% vs 74(64.8%</td>
<td>-</td>
<td>58(36.5% vs 58(35.2%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources

**Identification of studies via databases and registers**

- Records identified from:
  - Databases (n=2047)
  - Registers (n=23)

- Records screened (n=950)

- Reports sought for retrieval (n=48)

- Reports assessed for eligibility (n=48)
  - Studies included in review (n=6)
  - Reports of included studies (n=8)

**Identification of studies via other methods**

- Records removed before the screening:
  - Duplicate records removed (n=1120)

- Records excluded on the basis of title and abstract screening (n=902)

- Reports not retrieved (n=0)

- Reports sought for retrieval (n=7)

- Reports assessed for eligibility (n=7)
  - Reports excluded:
    - Usable data not provided (n=28)
    - Not an RCT (n=7)
    - Lack of control group (n=5)

- Reports not retrieved (n=0)

- Reports sought for retrieval (n=7)

- Reports assessed for eligibility (n=7)
  - Reports excluded:
    - Usable data not provided (n=5)
    - Not an RCT (n=2)
<table>
<thead>
<tr>
<th>Study</th>
<th>D1</th>
<th>D2</th>
<th>D3</th>
<th>D4</th>
<th>D5</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANGEL-ASPECT</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>LASTE</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>RESCUE-Japan LIMIT</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>SELECT2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>TENSION</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>TESLA</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Domains:
D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.
<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Events</th>
<th>Total</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>IV, Random, 95% CI</td>
<td>IV, Random, 95% CI</td>
</tr>
<tr>
<td>ANGEL-ASPECT</td>
<td>69</td>
<td>230</td>
<td>2.60 [1.72, 3.92]</td>
<td></td>
</tr>
<tr>
<td>LASTE</td>
<td>21</td>
<td>159</td>
<td>2.72 [1.24, 5.97]</td>
<td></td>
</tr>
<tr>
<td>RESCUE-Japan LIMIT</td>
<td>14</td>
<td>100</td>
<td>1.78 [0.78, 4.07]</td>
<td></td>
</tr>
<tr>
<td>SELECT2</td>
<td>36</td>
<td>177</td>
<td>2.90 [1.56, 5.38]</td>
<td></td>
</tr>
<tr>
<td>TENSION</td>
<td>21</td>
<td>124</td>
<td>6.89 [2.11, 22.49]</td>
<td></td>
</tr>
<tr>
<td>TESLA</td>
<td>22</td>
<td>151</td>
<td>1.64 [0.86, 3.12]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>941</strong></td>
<td><strong>931</strong></td>
<td><strong>2.49 [1.89, 3.29]</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Total events</strong></td>
<td><strong>183</strong></td>
<td><strong>70</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity</strong></td>
<td></td>
<td></td>
<td>Tau² = 0.01; Chi² = 5.41, df = 5 (P = 0.37); I² = 7%</td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect</strong></td>
<td></td>
<td></td>
<td>Z = 6.48 (P &lt; 0.00001)</td>
<td></td>
</tr>
<tr>
<td><strong>Medical care</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Endovascular thrombectomy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Endovascular thrombectomy | Medical care
---|---
Study or Subgroup | Events | Total | Events | Total | Weight | Risk Ratio (IV, Random, 95% CI)
ANGEL-ASPECT | 108 | 230 | 75 | 225 | 25.9% | 1.41 [1.12, 1.77]
LASTE | 53 | 159 | 21 | 165 | 14.9% | 2.62 [1.66, 4.13]
RESCUE-Japan LIMIT | 31 | 100 | 13 | 102 | 10.9% | 2.43 [1.35, 4.37]
SELECT2 | 67 | 177 | 32 | 171 | 18.8% | 2.02 [1.40, 2.91]
TENSION | 39 | 124 | 16 | 122 | 12.6% | 2.40 [1.42, 4.06]
TESLA | 45 | 151 | 29 | 146 | 16.9% | 1.50 [1.00, 2.26]
Total (95% CI) | 941 | 931 | 100.0% | 1.90 [1.50, 2.40]
Total events | 343 | 186
Heterogeneity: $\tau^2 = 0.04$; $\chi^2 = 10.16$, df = 5 ($P = 0.07$); $I^2 = 51$
Test for overall effect: $Z = 5.36$ ($P < 0.00001$)